Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IRIX 
IRIDEX Corporation (IRIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: IRIX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -44.86% | Avg. Invested days 22 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.77M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) - | Beta 0.61 | 52 Weeks Range 0.78 - 2.41 | Updated Date 06/29/2025 |
52 Weeks Range 0.78 - 2.41 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Earnings Date
Report Date 2025-06-18 | When After Market | Estimate -0.12 | Actual -0.1008 |
Profitability
Profit Margin -14.61% | Operating Margin (TTM) -1.72% |
Management Effectiveness
Return on Assets (TTM) -9.54% | Return on Equity (TTM) -106.93% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12829343 | Price to Sales(TTM) 0.3 |
Enterprise Value 12829343 | Price to Sales(TTM) 0.3 | ||
Enterprise Value to Revenue 0.26 | Enterprise Value to EBITDA -3.61 | Shares Outstanding 16789000 | Shares Floating 11118197 |
Shares Outstanding 16789000 | Shares Floating 11118197 | ||
Percent Insiders 27.93 | Percent Institutions 18.76 |
Upturn AI SWOT
IRIDEX Corporation
Company Overview
History and Background
IRIDEX Corporation, founded in 1989, develops, manufactures, and markets innovative laser-based medical systems, delivery devices, and consumable instrumentation for the treatment of glaucoma and other ophthalmic diseases.
Core Business Areas
- Glaucoma: Develops and markets laser systems and delivery devices for glaucoma treatment, including Cyclo G6 laser system and MicroPulse transscleral laser therapy (MP-TLT).
- Retinal: Offers laser systems and delivery devices for treating retinal diseases such as diabetic macular edema (DME) and retinal tears.
- OEM: Provides laser sub-systems for integration into other companies' medical devices.
Leadership and Structure
Dominique Beckers serves as the President and CEO. The company has a typical corporate structure with departments for research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- Cyclo G6 Glaucoma Laser System: A laser system for treating glaucoma using MicroPulse TLT technology. Competitors include Lumenis and Ellex. Market share for MicroPulse TLT within the glaucoma laser market is estimated to be growing, but specific figures are difficult to ascertain.
- IQ 577 Laser System: A multi-wavelength laser system for retinal and glaucoma applications. Competitors include Topcon, NIDEK, and Ellex. Again, specific market share data is challenging to obtain due to the broader multi-wavelength laser market.
Market Dynamics
Industry Overview
The ophthalmic laser market is driven by an aging population, increasing prevalence of diabetes (leading to retinal diseases), and rising awareness of glaucoma. Growth is also fueled by technological advancements in laser therapies.
Positioning
IRIDEX is positioned as a leader in MicroPulse laser technology for glaucoma treatment, offering a less invasive alternative to traditional glaucoma surgeries. Its competitive advantages lie in its proprietary MicroPulse technology and focus on ophthalmology.
Total Addressable Market (TAM)
The global ophthalmic laser market is estimated to be in the billions of USD. IRIDEX is well-positioned within segments of this TAM, particularly in glaucoma treatment and retinal photocoagulation, focusing on MicroPulse technology.
Upturn SWOT Analysis
Strengths
- Proprietary MicroPulse technology
- Focus on ophthalmology
- Established distribution network
- Strong brand reputation in glaucoma treatment
Weaknesses
- Relatively small company compared to larger competitors
- Limited product diversification
- Dependence on reimbursement rates for procedures
- Fluctuations in Capital
Opportunities
- Expanding applications of MicroPulse technology
- Growth in developing markets
- Strategic partnerships with other medical device companies
- New product development in related ophthalmic areas
Threats
- Competition from larger, more established companies
- Changes in reimbursement policies
- Technological advancements by competitors
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- LMNI
- ALEX
Competitive Landscape
IRIDEX faces competition from larger, more established players in the ophthalmic device market. Its advantage lies in its MicroPulse technology and focus on glaucoma treatment, but it needs to continue innovating and expanding its product portfolio to maintain its competitive position.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on past financial performance. Analysis would focus on revenue growth, profitability improvements, and market share gains.
Future Projections: Future projections are based on analyst estimates, which can vary. Factors considered include market trends, product pipeline, and competitive landscape.
Recent Initiatives: Recent strategic initiatives may include new product launches, partnerships, or acquisitions aimed at driving growth.
Summary
IRIDEX is a company focused on ophthalmic laser systems, particularly for glaucoma treatment. It has a strong position in MicroPulse technology. Competition is fierce, and the company needs to maintain innovation to succeed. Recent initiatives will determine future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Analyst estimates (where available)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IRIDEX Corporation
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 1996-02-15 | CEO, President & Director Mr. Patrick Mercer | ||
Sector Healthcare | Industry Medical Devices | Full time employees 93 | Website https://www.iridex.com |
Full time employees 93 | Website https://www.iridex.com | ||
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.